NASDAQ:ENGN | Free Cash Flow | enGene Therapeutics Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2022-10-31 to 2026-01-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-01-31-$28.9M$153,000.00-$29.06M
2025-10-31-$24.96M$437,000.00-$25.4M
2025-01-31-$25.7M$299,000.00-$26M
2024-10-31-$19.57M$238,000.00-$19.81M
2024-01-31-$7.37M$506,000.00-$7.88M
2023-10-31-$6.78M$138,000.00-$6.91M
2023-01-31-$6.22M$13,000.00-$6.24M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-10-31-$99.24M$1.49M-$100.72M
2024-10-31-$48.28M$925,000.00-$49.21M
2023-10-31-$24.74M$318,000.00-$25.06M
2022-10-31-$17.59M$153,000.00-$17.75M